SCHEMBL3028170

SCHEMBL3028170

CCCCCCCCCCCCCCCC(=O)OCC(O)CN(CCCCC(N)C(=O)OC(C)(C)C)CC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ TLR2 O60603 2/20 0.47
▸ PRKCA P17252 1/20 0.46
▸ PRKCE Q02156 1/20 0.46
▸ PRKCQ Q04759 1/20 0.46
▸ PRKCD Q05655 1/20 0.46
▸ LPAR3 Q9UBY5 6/20 0.44
▸ LPAR1 Q92633 3/20 0.44
▸ ENPP2 Q13822 3/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ LPAR2 Q9HBW0 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ DUSP3 P51452 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3036594 1.00 LMNA (0.51) LMNAALDH1A1TLR2PRKCAPRKCE
SCHEMBL3028306 0.96 ALDH1A1 (0.55) LMNAALDH1A1TLR2PRKCAPRKCE
SCHEMBL3030628 0.96 ALDH1A1 (0.55) LMNAALDH1A1TLR2PRKCAPRKCE
SCHEMBL3034803 0.96 ALDH1A1 (0.55) LMNAALDH1A1TLR2PRKCAPRKCE
SCHEMBL3027565 0.94 ALDH1A1 (0.50) LMNAALDH1A1TLR2PRKCAPRKCE
SCHEMBL3392589 0.94 ALDH1A1 (0.50) LMNAALDH1A1TLR2PRKCAPRKCE
SCHEMBL3392153 0.94 ALDH1A1 (0.50) LMNAALDH1A1TLR2PRKCAPRKCE
SCHEMBL3037068 0.93 LMNA (0.48) LMNAALDH1A1TLR2LPAR3LPAR1
SCHEMBL3028631 0.93 LMNA (0.48) LMNAALDH1A1TLR2LPAR3LPAR1
SCHEMBL3028169 0.93 LMNA (0.48) LMNAALDH1A1TLR2LPAR3LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100202998-A1 USE OF AT LEAST ONE LYSINE-DERIVED COMPOUND FOR THE CONDITIONING OF KERATINOUS FIBERS, COSMETIC COMPOSITION COMPRISING IT AND METHOD FOR CONDITIONING THE FIBERS L'OREAL S.A. (FR) 2010-08-12 — — US claimed
US-20100202998-A1 USE OF AT LEAST ONE LYSINE-DERIVED COMPOUND FOR THE CONDITIONING OF KERATINOUS FIBERS, COSMETIC COMPOSITION COMPRISING IT AND METHOD FOR CONDITIONING THE FIBERS L'OREAL S.A. (FR) 2010-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100202998-A1 USE OF AT LEAST ONE LYSINE-DERIVED COMPOUND FOR THE CONDITIONING OF KERATINOUS FIBERS, COSMETIC COMPOSITION COMPRISING IT AND METHOD FOR CONDITIONING THE FIBERS KRT18, DSG1, PLOD3 LMNA 520/4885ALDH1A1 674/4885TLR2 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback